Search
PTC Therapeutics Inc
PTCTAdd to Watchlist
68.970USD
+0.850+1.25%
Close 11-04 16:00（ET）
5.76BMarket Cap
LossP/E TTM
PTC Therapeutics Inc (PTCT) Stock Price Target & Forecast
Analyst Rating
Based on 15 analysts giving stock ratings to PTC Therapeutics Inc in the past month.
Buy
5 Strong Buy
8 Buy
2 Hold
0 Sell
0 Strong Sell
Target Price
98.400USD+56.14%
PTCT Analyst Recommendation Trends
In the current month, PTCT has received 8 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. PTCT average Analyst price target in the last month is 98.400.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
5
5
4
4
4
3
2
2
8
8
8
8
8
8
8
7
2
2
2
2
2
3
5
5
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
15
16
15
15
15
15
16
15
PTCT Analyst Rating for Peer Comparison
Updated: Nov 1, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
10
17
10
1
0
38
Amgen Inc
AMGN
4
9
19
3
1
36
Eli Lilly and Co
LLY
10
19
3
1
0
33
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Alnylam Pharmaceuticals Inc
ALNY
5
18
9
0
0
32
AbbVie Inc
ABBV
8
18
6
0
0
32
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Merck & Co Inc
MRK
7
15
9
0
0
31
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30
Gilead Sciences Inc
GILD
7
18
5
0
0
30
Financial Forecasting
Based on analysts' estimates, PTCT EPS is projected to reach 0.391 in FY2026Q4, following reported EPS of -0.619 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.47
0.42
0.34
0.39
0.38
Actual
-0.03
1.01
-0.62
--
--
Surprise
+92.76%
+141.27%
-281.31%
--
--
FAQs
What is PTC Therapeutics Inc's expected revenue for the next quarter?
PTC Therapeutics Inc's expected revenue is 330.53M.
What is PTC Therapeutics Inc's price target?
Analysts forecast that PTC Therapeutics Inc's price target is USD 101.07, with the highest forecast at USD 137.00 and the lowest forecast at USD 62.00.
How have PTC Therapeutics IncPTCT's recent earnings per share performed?
The market expectation was USD -0.62, while PTC Therapeutics IncPTCT's earnings per share (EPS) for the previous quarter was USD 1.01. EPS for the next quarter is expected at USD 0.39.
What is the analyst rating for PTC Therapeutics Inc?
Based on the ratings of PTC Therapeutics Inc's stock from 15 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.